How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Nenhuma Miniatura disponível




Perini, Guilherme Fleury
Fischer, Thais
Gaiolla, Rafael Dezen [UNESP]
Rocha, Talita Bueno
Bellesso, Marcelo
Teixeira, Larissa Lane Cardoso
Delamain, Marcia Torresan
Scheliga, Adriana Alves de Souza
Ribeiro, Glaciano Nogueira
Neto, Jorge Vaz

Título da Revista

ISSN da Revista

Título de Volume



The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.



Chronic lymphocytic leukemia, Coronavirus, CoVid, CoVId-19, Lymphoid malignancies, Lymphoma

Como citar

Hematology, Transfusion and Cell Therapy, v. 42, n. 2, p. 103-110, 2020.